Last updated: March 2, 2026
What is NDC 51672-4051?
NDC 51672-4051 corresponds to Venclexta (venetoclax), produced by AbbVie. It is a BCL-2 inhibitor approved for treating chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). The drug entered the market in 2016.
Current Market Position
Venclexta holds a significant share in the hematology-oncology segment, competing chiefly with BTK inhibitors (e.g., ibrutinib) and IDH inhibitors. Market penetration is strong in U.S. hematology practices with an expanding international footprint.
Market Size (2022)
| Metric |
Data |
| Global AML drugs market value |
$740 million (2023 estimates) |
| U.S. CLL market size |
~$3 billion (2022) |
| Venclexta's U.S. sales (2022) |
~$1.2 billion (company reports) |
| Market share in CLL therapy |
~40% (within targeted therapies) |
Sources: IQVIA,.company filings, Evaluate Pharma.
Competitive Landscape
| Competitors |
Key Drugs |
Approximate Market Share (2022) |
| Ibrutinib (Imbruvica) |
BTK inhibitor |
35-40% |
| Acalabrutinib (Calquence) |
BTK inhibitor |
10-15% |
| Venetoclax (Venclexta) |
BCL-2 inhibitor |
25-30% |
| Other agents |
IDH inhibitors, CAR-T therapies |
Remainder |
Venclexta's positioning relies on combination therapies and expanded indications. It is often used with rituximab for CLL, which bolsters its prescription rate.
Market Drivers
- Increasing diagnosis rates of CLL and AML.
- Expanding indications, including newly approved AML treatments.
- Combination therapy use, especially with obinutuzumab, enhancing efficacy.
- New international approvals, notably in Europe and Asia.
- Growing adoption in outpatient settings, reducing healthcare costs.
Price Trends and Projections
Current Pricing (2023)
| Region |
Estimated Wholesale Acquisition Cost (WAC) |
Remarks |
| U.S. |
~$13,000 per month |
For a typical 28-tablet pack |
| Europe |
Similar, with regional adjustments |
Price varies by country |
| Canada |
Slightly lower |
Price set through pharmacare programs |
Price Dynamics (2016–2023)
- Initial WAC was approximately $11,000 per month.
- Price increases in subsequent years averaged 3-5% annually.
- Influenced by manufacturing costs, market demand, and payer negotiations.
Future Price Projections (2024–2028)
| Year |
Estimated WAC (monthly) |
Assumptions |
| 2024 |
~$13,500 |
Slight annual increases, market saturation limit applies |
| 2025 |
~$14,000 |
Potential introduction of biosimilars or generics in select regions |
| 2026 |
~$14,500 |
Increasing adoption of combination regimens |
| 2027 |
~$15,000 |
Price stabilization after patent protections weaken |
| 2028 |
~$15,500 |
Potential price erosion due to biosimilar entry |
Note: Assumes continued demand growth and moderate inflation.
Impact of Biosimilars & Generics
As of 2023, no biosimilars for venetoclax exist commercially. Patent expiration around 2032 could enable generics, exerting downward pressure on prices, especially in Europe and emerging markets.
Revenue Projections
In 2022, Venclexta generated approximately $1.2 billion in revenue globally. Assuming market retention and expansion, revenues are projected as follows:
| Year |
Global Revenue (USD) |
Key Factors |
| 2023 |
~$1.4 billion |
Market expansion, new approvals |
| 2024 |
~$1.6 billion |
Growth in non-U.S. markets |
| 2025 |
~$1.8 billion |
Combination therapies increase use |
| 2026 |
~$2 billion |
Further indication approvals |
| 2027 |
~$2.2 billion |
Patent protections persist |
Regulatory and Market Risks
- Patent expiry could dilute market share.
- Competition from emerging therapies (e.g., CAR-T, newer targeted agents).
- Pricing pressures from payers and government negotiations.
- Potential safety concerns affecting prescribing behavior.
Key Takeaways
- NDC 51672-4051 (Venclexta) commands a premium price, with a robust revenue base driven by solid clinical efficacy.
- Market share is competitive, with ongoing expansion into AML and new indications.
- Price growth is moderate, with potential downward pressure from biosimilar and generic entries post-2032.
- Revenue growth aligns closely with increasing adoption, combination use, and international expansion.
- Risks include patent cliffs, competitive pipeline developments, and regulatory shifts.
FAQs
-
What factors influence Venclexta’s future pricing?
Price influences include patent protection, biosimilar/generic entry, payer negotiations, and demand growth.
-
When is patent expiration expected?
Patent protections in the U.S. are generally expected to expire around 2032, opening the market to generics.
-
How does Venclexta compare cost-wise to rivals?
It is priced similarly to other targeted leukemia therapies, with slight variations based on region and negotiated discounts.
-
What are the main growth opportunities?
Expanding indications in AML, new combination regimens, and increased international access present growth avenues.
-
What market risks could affect revenue projections?
Patent expiry, emergent therapies, regulatory changes, and payer pressure are key risks.
References
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] Evaluate Pharma. (2023). Global Oncology Market Forecast.
[3] AbbVie. (2022). Annual Report.
[4] FDA. (2016). Venclexta approval announcement.
[5] European Medicines Agency. (2022). Venclexta authorization.
